Maxion Therapeutics is pioneering the development of innovative protein therapeutics through its proprietary KnotBody® technology, which is designed to address previously untreatable diseases linked to ion channels and G protein-coupled receptors (GPCRs). This technology leverages naturally occurring cysteine-rich miniproteins, known as Knottins, which have evolved over millions of years to effectively target these complex biological structures. By integrating these miniproteins into antibody binding loops, Maxion aims to enhance the selectivity, potency, and manufacturability of its therapeutics, thereby overcoming the limitations associated with traditional small molecule drugs that often suffer from poor efficacy and significant side effects.

The KnotBody® technology represents a significant advancement in the field of drug discovery, particularly for conditions such as chronic pain, autoimmune disorders, and cardiovascular diseases, which affect millions globally. By focusing on the unique properties of engineered antibodies, Maxion Therapeutics is positioned to create first-in-class and best-in-class therapies that are not only safe and effective but also long-acting. This innovative approach addresses critical challenges in the pharmaceutical landscape, particularly in targeting ion channels and GPCRs, which have historically been difficult to drug effectively.

United Kingdom

Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

Maxion Therapeutics

Company Details